Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys
批准号:
10662323
负责人:
Sallie R. Permar
金额:
$275.52万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-07-24 至 2025-06-30
关键词:
AccelerationAnimal ModelAnimalsAwarenessBrain InjuriesCellular ImmunityClinical TrialsComplexCongenital AbnormalityCytomegalovirusCytomegalovirus VaccinesDecision MakingDevelopmentDiseaseFc ReceptorFetal DiseasesFetal ReductionFutureGeneticGlycoproteinsGoalsHumanHumoral ImmunitiesImmuneImmune TargetingImmune responseImmunocompetentImmunoglobulin GImmunologicsImpairmentInfantInfectionInfrastructureInstitute of Medicine (U.S.)KnowledgeLengthLymphocyte DepletionMacaca mulattaModelingNeurologicNeurologic DeficitNewborn InfantOutcomePopulation DynamicsPopulation GeneticsPreclinical TestingPreventionPrevention strategyProductionQuality of lifeResearchResourcesRhesusRoleStatistical Data InterpretationTestingVaccine ResearchVaccinesVariantViralViral GenomeVirusVirus DiseasesWorkclinically relevantcongenital cytomegaloviruscongenital infectiondesigndisease transmissioneffective interventionfetalfetal lossgenetic selectiongenome sequencingimmunoregulationimprovedin vivo evaluationinfant morbiditymathematical modelnext generationnonhuman primatenovelnovel strategiespregnantpressurepreventprogramsprotective efficacyrational designresearch clinical testingresponsetransmission processvaccine candidatevaccine developmentvaccine evaluationvaccine strategyvaccine trialviral transmissionvirus geneticswhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT – Immunologic and virologic determinants of congenital cytomegalovirus transmission
and disease in rhesus monkeys.
Congenital cytomegalovirus (CMV) is the leading infectious cause of birth defects and infant neurologic
deficits, yet gaps in our knowledge of the protective maternal immune responses has impeded the
development of a successful CMV vaccine to eliminate this cause of infant morbidity. The overarching goal of
this Program is to end the stalemate in congenital CMV vaccine research by defining the key immune
responses and viral-host interactions that dictate primary fetal CMV transmission and disease. To accomplish
this, the Program builds on our novel nonhuman primate (NHP) model of placental transmission of rhesus
CMV (RhCMV). Specifically, the Program will employ this newly defined NHP model in RhCMV-seronegative
pregnant dams to investigate the immune correlates of placental virus transmission and fetal disease (Project
1) and the viral determinants of placental RhCMV transmission (Project 2). An Administrative Core and four
scientific Cores provide critical expertise and resources required to integrate Program activities, including
administrative infrastructure and oversight (Administrative Core), NHP study implementation expertise (Core
1), virus production and quantitation (Core 2), whole viral genome sequencing and population genetics (Core
3) and statistical analyses and mathematical modeling (Core 4). Our overall hypothesis is that maternal
humoral and cellular immunity provides partial protection against placental CMV transmission and disease, and
viral-host immune interactions determine the emergence of both placentally transmitted and fetal CMV
variants. Our overall specific aims are: 1) Demonstrate whether CMV-specific humoral and/or cellular
responses confer protective efficacy against congenital infection and fetal disease; and 2) Define the key
virologic determinants and viral selection pressures of placental CMV transmission and subsequent fetal
disease. We expect the work of this Program will identify immune responses and virologic-host interactions
that will guide the design of the next generation of congenital CMV vaccines and will also refine the NHP model
to tailor it for future CMV vaccine candidate testing.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
猕猴预先存在的巨细胞病毒免疫力影响临床前模型中人类 CMV 疫苗的反应。
DOI:
10.1016/j.vaccine.2021.08.011
发表时间:
2021
期刊:
Vaccine
影响因子:
5.5
作者:
[Webster,Helen, Valencia,Sarah, Kumar,Amit, Chan,Cliburn, Dennis,Maria, Roark,Hunter, Woods,Angela, John,Shinu, Carfi,Andrea, Permar,SallieR]
通讯作者:
Permar,SallieR
DOI:
10.3390/v13061106
发表时间:
2021-06-09
期刊:
Viruses
影响因子:
--
作者:
[Wang HY, Valencia SM, Pfeifer SP, Jensen JD, Kowalik TF, Permar SR]
通讯作者:
Permar SR
Heterosubtypic, cross-reactive immunity to human Cytomegalovirus glycoprotein B.
对人巨细胞病毒糖蛋白 B 的异亚型交叉反应免疫。
DOI:
10.1093/cei/uxac031
发表时间:
2022
期刊:
Clinical and experimental immunology
影响因子:
4.6
作者:
[Bilgilier,Ceren, Schneider,Martina, Kührer,Kristina, Kilb,Normann, Hartl,Ramona, Topakian,Thais, Kastner,Marie-Theres, Herz,Tobias, Nelson,CodyS, Permar,SallieR, Roth,Günter, Steininger,Christoph]
通讯作者:
Steininger,Christoph
DOI:
10.1084/jem.20230184
发表时间:
2023-07-03
期刊:
JOURNAL OF EXPERIMENTAL MEDICINE
影响因子:
15.3
作者:
[Crooks, Chelsea M., Chan, Cliburn, Permar, Sallie R.]
通讯作者:
Permar, Sallie R.
Identifying and modeling immune correlates of protection against congenital CMV transmission after primary maternal infection
-
批准号:10677439
-
项目类别:
-
资助金额:$84.84万
-
财政年份:2023
-
负责人:Sallie R. Permar
-
依托单位:
Pediatric Scientist Development Program
-
批准号:10619351
-
项目类别:
-
资助金额:$153.57万
-
财政年份:2022
-
负责人:Sallie R. Permar
-
依托单位:
Escape of maternal plasma broadly neutralizing antibody as a mechanism of mother to child HIV transmission
-
批准号:10327003
-
项目类别:
-
资助金额:$74.42万
-
财政年份:2021
-
负责人:Sallie R. Permar
-
依托单位:
Pediatric Scientist Development Program
-
批准号:10349771
-
项目类别:
-
资助金额:$87.5万
-
财政年份:2020
-
负责人:Sallie R. Permar
-
依托单位:
Pediatric Scientist Development Program
-
批准号:10220089
-
项目类别:
-
资助金额:$140.96万
-
财政年份:2020
-
负责人:Sallie R. Permar
-
依托单位:
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques
-
批准号:10223633
-
项目类别:
-
资助金额:$13.75万
-
财政年份:2020
-
负责人:Sallie R. Permar
-
依托单位:
Project-003
-
批准号:10461206
-
项目类别:
-
资助金额:$26.56万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Core-001
-
批准号:10461201
-
项目类别:
-
资助金额:$28.0万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Project-003
-
批准号:10441007
-
项目类别:
-
资助金额:$25.81万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Core-004
-
批准号:10441005
-
项目类别:
-
资助金额:$16.83万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Project 1: Immune correlates of cCMV
-
批准号:10215784
-
项目类别:
-
资助金额:$0.19万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Core 2: Virology, Molecular, and Histology Core
-
批准号:10215781
-
项目类别:
-
资助金额:$0.23万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Core 3: Genomic Sequencing and Population Genetics Core
-
批准号:10215782
-
项目类别:
-
资助金额:$0.22万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Core-001
-
批准号:10441002
-
项目类别:
-
资助金额:$108.26万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys
-
批准号:10402416
-
项目类别:
-
资助金额:$294.82万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Core 3: Genomic Sequencing and Population Genetics Core
-
批准号:10374246
-
项目类别:
-
资助金额:$33.86万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Core 2: Virology, Molecular, and Histology Core
-
批准号:10374245
-
项目类别:
-
资助金额:$45.38万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Project-002
-
批准号:10662366
-
项目类别:
-
资助金额:$50.91万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Project-003
-
批准号:10662367
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
Core-003
-
批准号:10461203
-
项目类别:
-
资助金额:$14.17万
-
财政年份:2019
-
负责人:Sallie R. Permar
-
依托单位:
海外基金